Legend Biotech Corporation (LEGN) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LEGN Revenue Growth
Revenue Breakdown (FY 2021)
LEGN's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
By Geography
LEGN Revenue Analysis (2017–2025)
As of May 8, 2026, Legend Biotech Corporation (LEGN) generated trailing twelve-month (TTM) revenue of $1.03 billion, reflecting explosive growth of +64.9% year-over-year. The most recent quarter (Q4 2025) recorded $307.6 million in revenue, up 13.0% sequentially.
Looking at the longer-term picture, LEGN's 5-year compound annual growth rate (CAGR) stands at +68.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $1.03 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows LEGN's business is primarily driven by Licensing Of Intellectual Property (100%). With over half of revenue concentrated in Licensing Of Intellectual Property, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including FATE (-51.2% YoY), CRSP (-88.9% YoY), and BEAM (+108.0% YoY), LEGN has underperformed the peer group in terms of revenue growth. Compare LEGN vs FATE →
LEGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LEGNCurrent | $1.0B | +64.9% | +68.9% | -13.3% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% |
LEGN Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.03B | +64.5% | $622.4M | 60.3% | $-136,861,006 | -13.3% |
| 2024 | $627.2M | +120.0% | $392.7M | 62.6% | $-303,243,000 | -48.3% |
| 2023 | $285.1M | +143.7% | $140.9M | 49.4% | $-439,485,000 | -154.1% |
| 2022 | $117.0M | +70.0% | $51.6M | 44.1% | $-455,620,000 | -389.4% |
| 2021 | $68.8M | -8.2% | $68.8M | 100.0% | $-392,287,000 | -570.0% |
| 2020 | $75.0M | +21.4% | $75.0M | 100.0% | $0 | - |
| 2019 | $61.8M | +25.8% | $61.8M | 100.0% | $-132,514,000 | -214.4% |
| 2018 | $49.1M | +108.2% | $49.1M | 100.0% | $-1,534,000 | -3.1% |
| 2017 | $23.6M | - | $23.7M | 100.4% | $13.8M | 58.4% |
See LEGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LEGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LEGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLEGN — Frequently Asked Questions
Quick answers to the most common questions about buying LEGN stock.
Is LEGN's revenue growth accelerating or slowing?
LEGN revenue is accelerating at +64.9% year-over-year, exceeding the 5-year CAGR of +68.9%. TTM revenue reached $1.0B. Growth momentum has increased versus prior periods.
What is LEGN's long-term revenue growth rate?
Legend Biotech Corporation's 5-year revenue CAGR of +68.9% reflects the sustained expansion pattern. Current YoY growth of +64.9% is above this long-term average.
How is LEGN's revenue distributed by segment?
LEGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.